Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Calgary

$17,500.00

Remote Ischemic Pre-conditioning as a Remyelination Enhancement Therapy

EF 2022-23

Résumé
Multiple sclerosis (MS) is a neurodegenerative disease that results in demyelination which is the stripping of myelin from nerve fibers and axonal damage, leading to loss of motility and vision problems. MS affects 93,500 Canadians with models predicting the number to rise to 130,000 Canadians and cost the health sector two billion dollars by 2031. A key issue that causes the debilitation of MS patients is they lose the ability to remyelinate which is reforming myelin sheaths around axons. Heightening this issue is that there are few MS therapies that enhance remyelination. Due to this my research is focused on therapies that can enhance remyelination and the mechanisms by which it is achieved. One of the therapies I believe could enhance remyelination is remote ischemic preconditioning (RIPC). RIPC involves subjecting distant parts of the body to brief periods of loss of blood flow followed by reperfusion. This method provides protection to future severe ischemic episodes. Research has shown that RIPC also has neuroprotective effects via internal mechanisms. My project aims to examine if RIPC has significant effects on the expression of internal factors that are essential for remyelination. The relationship between these factors will be investigated as well. To study de-and re-myelination I’ll be using a mouse model where lysolecithin is injected in the mice spinal cord to induce demyelination and lesions characteristic of MS. If results are promising RIPC can be easily translated for human studies. There is an urgent need for therapies that enhance remyelination. MS patients would greatly benefit as with increasing remyelination there would be less axonal damage, which can lead to less severe symptoms and less patients progressing up the disability status scale.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
488146
Name
Phillips Serena A
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Remote Ischemic Pre-conditioning as a Remyelination Enhancement Therapy
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Demyelination; Endogenous Mechanisms; Multiple Sclerosis; Neurodegeneration; Neurprotection; Remote Ischemic Pre-Conditioning; Remyelination; Therapies
Abstract
Multiple sclerosis (MS) is a neurodegenerative disease that results in demyelination which is the stripping of myelin from nerve fibers and axonal damage, leading to loss of motility and vision problems. MS affects 93,500 Canadians with models predicting the number to rise to 130,000 Canadians and cost the health sector two billion dollars by 2031. A key issue that causes the debilitation of MS patients is they lose the ability to remyelinate which is reforming myelin sheaths around axons. Heightening this issue is that there are few MS therapies that enhance remyelination. Due to this my research is focused on therapies that can enhance remyelination and the mechanisms by which it is achieved. One of the therapies I believe could enhance remyelination is remote ischemic preconditioning (RIPC). RIPC involves subjecting distant parts of the body to brief periods of loss of blood flow followed by reperfusion. This method provides protection to future severe ischemic episodes. Research has shown that RIPC also has neuroprotective effects via internal mechanisms. My project aims to examine if RIPC has significant effects on the expression of internal factors that are essential for remyelination. The relationship between these factors will be investigated as well. To study de-and re-myelination I’ll be using a mouse model where lysolecithin is injected in the mice spinal cord to induce demyelination and lesions characteristic of MS. If results are promising RIPC can be easily translated for human studies. There is an urgent need for therapies that enhance remyelination. MS patients would greatly benefit as with increasing remyelination there would be less axonal damage, which can lead to less severe symptoms and less patients progressing up the disability status scale.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Phillips, Serena A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~